By FieldPulse Staff · March 18, 2026
Tags: launch, strategy, field
J&J's once-daily psoriasis pill Icotyde approved March 18 — the first oral IL-23 inhibitor. J&J eyes $5B+ peak sales. AbbVie's Skyrizi and J&J's own Tremfya now face oral competition.
Johnson & Johnson received FDA approval on March 18, 2026 for Icotyde (icotrokinra), making it the first oral IL-23 inhibitor cleared for moderate-to-severe plaque psoriasis in patients aged 12 and older. The once-daily pill enters a market dominated by injectable biologics, including AbbVie's Skyrizi (risankizumab) and J&J's own Tremfya (guselkumab) — both subcutaneous injections. J&J projects peak annual sales exceeding $5 billion, positioning Icotyde as a major growth driver for its immunology franchise. The approval creates a significant new competitive dynamic in dermatology: for the firs